TEST CHANGE

Urticaria-Inducing Activity with Thyroid Antibodies and Stimulating Hormone

2005415, UIAT

Specimen Requirements:	
Patient Preparation:	Patients taking calcineurin inhibitors should stop their medication 72 hours prior to draw. Patients on prednisone should be off their medication for 2 weeks prior to draw.
Collect:	Plain red.
Specimen Preparation:	Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum each to twoan ARUP standard transport tubesStandard Transport tube and freeze immediately (Min: 0.5 mL each) AND transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Transport Temperature:	First Specimen: CRITICAL FROZEN. Separate specimens must be submitted for this multiple test panel. Second Specimen: Refrigerated.
Unacceptable Conditions:	Specimens other than serum. Contaminated, grossly hemolyzed, or lipemic specimens.
Remarks:	
Stability:	First Specimen: After separation from cells: Ambient: 30 minutes; Refrigerated: Unacceptable; Frozen: 1 year (avoid repeated freeze/thaw cycles) Second Specimen: After separation from cells: Ambient: 8 hours; Refrigerated: 1 Week; Frozen: 6 months
Methodology:	Semi-Quantitative Ex Vivo Challenge/Cell Culture/Quantitative Enzyme-Linked Immunosorbent Assay (ELISA)/Quantitative Chemiluminescent Immunoassay (CLIA)
Performed:	Mon, Fri
Reported:	11-14 days
Note:	1) Chronic urticaria (CU) is a common and complex dermatological condition that is suspected when patients experience persistent hives for over 6 weeks. No published evidence of an exogenous allergen as the cause of this disorder exists. About 45 percent of cases have autoantibodies directed against either basophil or mast cell-associated IgE or the high-affinity IgE-Fc receptor (Fc epsilon R1 alpha) (Clin Exp Allergy

	2009; 39: 777-87). 2) The presence of histamine-releasing factors (including but not limited to IgE and Fc epsilon R1 alpha-specific autoantibodies) in the patient serum can be indirectly determined by evaluating basophil/mast cell activation status using histamine-release assays, autologous serum-skin test, and flow cytometric measurement of the basophil and mast cell-specific marker CD203c. Serum from CU patients can activate donor basophils, which induces histamine release and CD203c upregulation (J Allergy Clin Immunol 2006; 117: 1430-4).
CPT Codes:	86352; 86800; 84443; 86376
New York DOH Approval Status:	This test is New York DOH approved.
Interpretive Data:	
Refer to report. ~~Refer to report.~~ ~~This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.~~	
Reference Interval:	
By report	